Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab + SOX ± apatinib in HER2-positive advanced gastric cancer
ChiCTR2100051574Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of inetetamab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoint: objective response rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
inetetamab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100051574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051574.